Renovacor, Inc.: insider trades · United States · SEC (Form 4)

About Renovacor, Inc.

Renovacor, Inc. (RCOR) was a U.S.-based biotechnology company that traded on the NYSE/NASDAQ ecosystem in the United States and focused on precision therapies for genetically driven cardiovascular disease. In its public filings, Renovacor described itself as an early-stage biotech developing innovative treatments for patients with inherited heart disorders and other mechanistically defined diseases. The company’s core strategy was rooted in AAV-based gene therapy, with an emphasis on rare, high-unmet-need indications where a targeted molecular approach could potentially offer meaningful clinical differentiation. Its lead program, REN-001, was designed around BAG3-associated dilated cardiomyopathy (BAG3-DCM), a serious inherited heart condition with limited disease-modifying treatment options. From an operational standpoint, Renovacor was a development-stage company rather than a commercial pharmaceutical business. Its value proposition depended on research execution, translational proof-of-concept work, and eventual regulatory progress, rather than on a diversified revenue base. Like many small-cap biotech names, it relied on external financing, capital markets access, and strategic optionality to advance its pipeline. Public disclosures indicated that Renovacor was incorporated in Delaware and operated in the United States, with historical references to facilities in Hopewell, New Jersey, and Cambridge, Massachusetts. Those locations are consistent with a biotech footprint embedded in established U.S. life-science hubs, especially along the East Coast and around Boston-area research ecosystems. In competitive terms, Renovacor occupied a specialized niche within cardiovascular gene therapy. Its potential edge came from a focused scientific thesis, a rare-disease target with significant unmet need, and intellectual property built around a narrowly defined mechanism of action. However, the company also faced the structural challenges typical of clinical-stage biotech: dependence on positive data, dilution risk, regulatory uncertainty, and competition from better-capitalized peers with broader development platforms. For investors, the key point is that Renovacor was not a broad-based cardiology platform but a highly focused gene-therapy developer with a concentrated pipeline and binary clinical risk profile. The most important recent corporate event was its acquisition by Rocket Pharmaceuticals, announced and then completed in 2022. As a result, Renovacor ceased to exist as an independent listed company, and the RCOR ticker is now part of market history rather than an active standalone equity story. The transaction transferred Renovacor’s programs, know-how, and personnel into Rocket’s broader rare-disease gene therapy strategy. Therefore, any analysis of legacy RCOR insider Form 4 activity should be viewed in the context of a company that has already been absorbed into a larger platform, not as a currently independent NYSE/NASDAQ issuer.